UVADEX Drug Patent Profile
✉ Email this page to a colleague
When do Uvadex patents expire, and what generic alternatives are available?
Uvadex is a drug marketed by Mallinckrodt Hosp and is included in one NDA.
The generic ingredient in UVADEX is methoxsalen. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methoxsalen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Uvadex
A generic version of UVADEX was approved as methoxsalen by STRIDES PHARMA on June 5th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for UVADEX?
- What are the global sales for UVADEX?
- What is Average Wholesale Price for UVADEX?
Summary for UVADEX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 150 |
| Clinical Trials: | 17 |
| Patent Applications: | 5,133 |
| Drug Prices: | Drug price information for UVADEX |
| What excipients (inactive ingredients) are in UVADEX? | UVADEX excipients list |
| DailyMed Link: | UVADEX at DailyMed |
Recent Clinical Trials for UVADEX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Central Hospital, Nancy, France | Phase 2 |
| Lawson Health Research Institute | Phase 2 |
| European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
Pharmacology for UVADEX
| Drug Class | Photoactivated Radical Generator Psoralen |
| Mechanism of Action | Photoabsorption |
| Physiological Effect | Photosensitizing Activity |
US Patents and Regulatory Information for UVADEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt Hosp | UVADEX | methoxsalen | INJECTABLE;INJECTION | 020969-001 | Feb 25, 1999 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for UVADEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mallinckrodt Hosp | UVADEX | methoxsalen | INJECTABLE;INJECTION | 020969-001 | Feb 25, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Mallinckrodt Hosp | UVADEX | methoxsalen | INJECTABLE;INJECTION | 020969-001 | Feb 25, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Mallinckrodt Hosp | UVADEX | methoxsalen | INJECTABLE;INJECTION | 020969-001 | Feb 25, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for UVADEX
See the table below for patents covering UVADEX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1340846 | ⤷ Sign Up | |
| Japan | S63119682 | DEVELOPMENT OF BIOLOGICALLY ACTIVE PDGE ANALOGUE IN EUCARYOTIC CELL | ⤷ Sign Up |
| Japan | H02290814 | PSORALEN REAGENT COMPOSITION | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for UVADEX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0177957 | C990016 | Netherlands | ⤷ Sign Up | PRODUCT NAME: BECAPLERMINUM; REGISTRATION NO/DATE: EU/1/99/101/001 19990329 |
| 0177957 | 99C0034 | Belgium | ⤷ Sign Up | PRODUCT NAME: BECAPLERMIN; REGISTRATION NO/DATE: EU/1/99/101/001 19990329 |
| 0177957 | SPC/GB99/023 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: BECAPLERMIN; REGISTERED: UK EU/1/99/101/001 19990329 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
